MRKR Share Price Performance
US$0.95
-1.83 (-65.65%)
Price US$0.95
Share PriceUS$0.95
Marker Therapeutics, Inc. Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 1 Fair Values set on narratives written by author
MRKR Community Narratives
There are no narratives available yet.
Recent MRKR News & Updates
Marker Therapeutics, Inc. Key Details
Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -1.13
- Gross Margin
- -194.54%
- Net Profit Margin
- -271.11%
- Debt/Equity Ratio
- 0%
Marker Therapeutics, Inc. Competitors
Snowflake Analysis
About MRKR
- Founded
- n/a
- Employees
- 5
- CEO
- WebsiteView website
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens. The company also develops MT-401-OTS for the treatment of acute myeloid leukemia AND myelodysplastic syndromes; and MT-601 to treat lymphoma and pancreatic cancer. Marker Therapeutics, Inc. is headquartered in Houston, Texas.
Market Insight
Rare earths may be a sliver of the global metals market, but they punch far above their weight. These obscure elements are the invisible wiring of modern life.
Continue reading
U.S. Market Performance
- 7 Days: 0.9%
- 3 Months: 8.7%
- 1 Year: 18.4%
- Year to Date: 14.8%
Over the last 7 days, the market has remained flat, although notably the Healthcare sector gained 6.4% in that time. As for the longer term, the market has risen 18% in the past 12 months. Looking forward, earnings are forecast to grow by 15% annually. Market details ›